Pfizer (PFE) Annoucnes XALKORI Phase 3 Met Primary Endpoint in ALK-Positive NSCLC
Tweet Send to a Friend
Pfizer (NYSE: PFE) announced today that PROFILE 1029, a Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor XALKORI (crizotinib) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
